A Phase 2 interventional study of Pirfenidone in Idiopathic Pulmonary Fibrosis and Pulmonary Fibrosis, sponsored by Genentech, Inc.. Completed at 27 sites in United States. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2017-04-17.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis — 2 open to participants now, 3 under way, 1 of them phase 3. pirfenidone · Idiopathic Pulmonary Fibrosis.
Among the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, this one is the 12th largest by enrollment, is the only one that started in 2003, is one of 6 in phase 2, and was the 1st registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →2 of the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis are open now, in 3 countries. Recruiting first, the newest first:
PureTech · Sites in United States, Canada
Ages 40+
Assiut University · Sites in Egypt
Ages 18–80
By country, each count listing its studies:
pirfenidone: first FDA approval 2014 (ESBRIET), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 83 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 89 across the 21 interventional studies. Of the 17 that completed or were terminated, 9 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 21 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
29 studies in Idiopathic Pulmonary Fibrosis by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 27 finished, 15 (56%) have results posted.
Among the 29 studies in Idiopathic Pulmonary Fibrosis by Hoffmann-La Roche, this one is the 18th largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2003, is one of 9 in phase 2, and was the 7th registered.
Hoffmann-La Roche’s Idiopathic Pulmonary Fibrosis studies by the year they started, since 2000.
1 of the studies testing pirfenidone in Idiopathic Pulmonary Fibrosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05842681Assiut UniversityAzithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis | 2027-01-01 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 29 in Idiopathic Pulmonary Fibrosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess the safety of treatment with pirfenidone (up to 3600 mg/d) in patients with pulmonary fibrosis/idiopathic pulmonary fibrosis (PF/IPF).
This study has been designed as a rollover study to collectively include safety data from various previous studies.
In addition, InterMune has also initiated an Early Access Program to make pirfenidone available to a limited number of patients with idiopathic pulmonary fibrosis in the United States. This program is also being conducted under this protocol. Registration of patients with documented IPF has been closed as of October 2005.
General Inclusion Criteria:
Roll-Over Criteria:
Criteria for Early Access Program patients:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
up to 3600 mg/day of pirfenidone given orally administered in divided doses three times daily with food, for the duration of the study
Drug: Pirfenidone
up to 3600 mg/day of pirfenidone given orally administered in divided doses three times daily with food, for the duration of the study
Percentage of Participants With a Treatment-Emergent Adverse Event (AE), Serious AE (SAE), Severe AE, Life-threatening AE, Death or Discontinuation Because of an AE
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs were classified as severe (Grade 3) in following cases: marked limitation in activity; some assistance usually required; medical intervention/ therapy required, hospitalization possible. Treatment-emergent AEs were those occurring on or after the first dosing day and up to 28 days after discontinuation of study treatment, and those occurring before treatment that worsened after the first study dose. AE included serious as well as non-serious AEs.
Time frame: Baseline to 28 days after the last dose of study treatment (maximum duration of treatment in study was 604 weeks)
Percent Predicted Forced Vital Capacity (FVC)
FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. FVC is the volume of air that can forcibly be blown out from the lungs after full inspiration in the upright position, measured in liters. Predicted FVC is based on a formula using sex, age and height of a person, and is an estimate of healthy lung capacity. Percent of predicted FVC = (actual FVC value in liter)/(predicted FVC) \* 100%
Time frame: Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480
Hemoglobin (Hgb)-Corrected Percent-Predicted Carbon Monoxide Diffusing Capacity (DLco)
DLco is a pulmonary function test, and measures the partial pressure difference between inspired and expired carbon monoxide. Predicted DLco is based on a formula using sex, age and height of a person. Predicted DLco = \[Hbg-corrected DLco value (in milliliters per minute per millimeter mercury \[mL/min/mmHg\])/predicted DLco\] \* 100%
Time frame: Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480
Resting Oxygen Saturation by Pulse Oximetry (SpO2)
SpO2 is the percentage of oxygen saturation in the blood. Oxygen level (oxygen saturation) of the blood was measured using pulse oximetry on room air.
Time frame: Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480
Overall Survival
Survival was analyzed as time from first study dose to death (all-cause mortality) with surviving participants censored at their last available assessment.
Time frame: First dosing of study treatment until death (up to 604 weeks)
| Milestone | Pirfenidone |
|---|---|
| Started | 83 |
| Completed | 7 |
| Not completed | 76 |
| Withdrew: Adverse event | 23 |
| Withdrew: Death | 21 |
| Withdrew: Withdrawal by subject | 13 |
| Withdrew: Lung transplantation | 9 |
| Withdrew: Non-compliance with study treatment | 7 |
| Withdrew: Participant unwilling to continue | 2 |
| Withdrew: Physician decision | 1 |
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs were classified as severe (Grade 3) in following cases: marked limitation in activity; some assistance usually required; medical intervention/ therapy required, hospitalization possible. Treatment-emergent AEs were those occurring on or after the first dosing day and up to 28 days after discontinuation of study treatment, and those occurring before treatment that worsened after the first study dose. AE included serious as well as non-serious AEs.
| percentage of participants | Pirfenidone |
|---|---|
| Any AE | 98.8 |
| SAE | 59.0 |
| Severe AE | 36.1 |
| Life-threatening AE | 21.7 |
| AEs leading to death | 25.3 |
| AE leading to study treatment discontinuation | 43.4 |
FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. FVC is the volume of air that can forcibly be blown out from the lungs after full inspiration in the upright position, measured in liters. Predicted FVC is based on a formula using sex, age and height of a person, and is an estimate of healthy lung capacity. Percent of predicted FVC = (actual FVC value in liter)/(predicted FVC) \* 100%
| percent predicted FVC | Pirfenidone |
|---|---|
| Baseline (n=78) | 67.7 ± 18.70 |
| Week 24 (n=71) | 67.5 ± 17.11 |
| Week 48 (n=57) | 68.7 ± 17.36 |
| Week 72 (n=50) | 68.4 ± 16.20 |
| Week 96 (n=47) | 67.9 ± 17.76 |
| Week 120 (n=44) | 67.7 ± 18.03 |
| Week 144 (n=39) | 66.1 ± 18.22 |
| Week 168 (n=35) | 65.7 ± 17.74 |
| Week 192 (n=28) | 67.8 ± 18.32 |
| Week 216 (n=28) | 68.7 ± 21.97 |
| Week 240 (n=22) | 65.3 ± 16.80 |
| Week 264 (n=15) | 70.1 ± 13.26 |
| Week 288 (n=14) | 76.6 ± 18.71 |
| Week 312 (n=14) | 71.1 ± 14.03 |
| Week 336 (n=10) | 64.9 ± 13.61 |
| Week 360 (n=7) | 60.9 ± 15.00 |
| Week 384 (n=6) | 68.4 ± 17.43 |
| Week 408 (n=4) | 65.1 ± 11.84 |
| Week 432 (n=1) | 61.5 ± NA |
| Week 456 (n=1) | 78.4 ± NA |
| Week 480 (n=1) | 80.9 ± NA |
DLco is a pulmonary function test, and measures the partial pressure difference between inspired and expired carbon monoxide. Predicted DLco is based on a formula using sex, age and height of a person. Predicted DLco = \[Hbg-corrected DLco value (in milliliters per minute per millimeter mercury \[mL/min/mmHg\])/predicted DLco\] \* 100%
| percent predicted DLco | Pirfenidone |
|---|---|
| Baseline (n=74) | 38.0 ± 13.36 |
| Week 24 (n=65) | 39.5 ± 13.56 |
| Week 48 (n=55) | 37.1 ± 13.55 |
| Week 72 (n=49) | 37.0 ± 12.01 |
| Week 96 (n=44) | 38.0 ± 12.35 |
| Week 120 (n=41) | 35.7 ± 12.55 |
| Week 144 (n=37) | 38.5 ± 13.47 |
| Week 168 (n=33) | 36.7 ± 12.98 |
| Week 192 (n=27) | 37.2 ± 11.34 |
| Week 216 (n=28) | 35.8 ± 11.31 |
| Week 240 (n=22) | 35.5 ± 12.67 |
| Week 264 (n=15) | 37.5 ± 9.69 |
| Week 288 (n=14) | 42.9 ± 18.43 |
| Week 312 (n=14) | 38.6 ± 9.54 |
| Week 336 (n=10) | 33.7 ± 6.41 |
| Week 360 (n=7) | 37.1 ± 11.19 |
| Week 384 (n=5) | 38.3 ± 13.16 |
| Week 408 (n=4) | 38.1 ± 9.41 |
| Week 432 (n=1) | 33.9 ± NA |
| Week 456 (n=1) | 11.6 ± NA |
| Week 480 (n=1) | 38.9 ± NA |
SpO2 is the percentage of oxygen saturation in the blood. Oxygen level (oxygen saturation) of the blood was measured using pulse oximetry on room air.
| percentage of oxygen saturation | Pirfenidone |
|---|---|
| Baseline (n=72) | 94.5 ± 3.53 |
| Week 24 (n=55) | 94.4 ± 4.14 |
| Week 48 (n=47) | 94.8 ± 3.05 |
| Week 72 (n=41) | 94.9 ± 3.01 |
| Week 96 (n=36) | 94.9 ± 2.77 |
| Week 120 (n=35) | 94.8 ± 2.46 |
| Week 144 (n=33) | 94.8 ± 2.78 |
| Week 168 (n=25) | 94.0 ± 3.18 |
| Week 192 (n=22) | 94.9 ± 2.59 |
| Week 216 (n=23) | 95.2 ± 2.33 |
| Week 240 (n=17) | 95.5 ± 2.67 |
| Week 264 (n=11) | 95.7 ± 1.56 |
| Week 288 (n=10) | 94.6 ± 4.09 |
| Week 312 (n=11) | 95.8 ± 2.48 |
| Week 336 (n=9) | 94.4 ± 2.35 |
| Week 360 (n=7) | 94.9 ± 4.02 |
| Week 384 (n=7) | 94.0 ± 2.77 |
| Week 408 (n=6) | 94.8 ± 2.86 |
| Week 432 (n=1) | 95.0 ± NA |
| Week 456 (n=1) | 97.0 ± NA |
| Week 480 (n=3) | 95.0 ± 2.00 |
Survival was analyzed as time from first study dose to death (all-cause mortality) with surviving participants censored at their last available assessment.
| weeks | Pirfenidone |
|---|---|
| Overall Survival | 508.7 (264.14 to NA) |
Collected over Baseline to 28 days after the last dose of study treatment (maximum duration of treatment in study was 604 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pirfenidone | — | 49/83 (59%) | 81/83 (97.6%) |
| Event | Pirfenidone |
|---|---|
| Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 15/83 |
| PneumoniaInfections and infestations | 9/83 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 6/83 |
| Atrial fibrillationCardiac disorders | 4/83 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/83 |
| Coronary artery diseaseCardiac disorders | 3/83 |
| BronchitisInfections and infestations | 3/83 |
| Cardiac failure congestiveCardiac disorders | 2/83 |
| Myocardial infarctionCardiac disorders | 2/83 |
| Colitis ischaemicGastrointestinal disorders | 2/83 |
| Event | Pirfenidone |
|---|---|
| NauseaGastrointestinal disorders | 40/83 |
| FatigueGeneral disorders | 27/83 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 23/83 |
| Upper respiratory tract infectionInfections and infestations | 21/83 |
| CoughRespiratory, thoracic and mediastinal disorders | 21/83 |
| Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 21/83 |
| Weight decreasedInvestigations | 18/83 |
| RashSkin and subcutaneous tissue disorders | 16/83 |
| InsomniaPsychiatric disorders | 15/83 |
| Decreased appetiteMetabolism and nutrition disorders | 14/83 |
All treated participants
| Age, Continuous(years) | Pirfenidone |
|---|---|
| Mean | 68.5 ± 9.15 |
| Sex: Female, Male(Participants) | Pirfenidone |
|---|---|
| Female | 23 |
| Male | 60 |
Ran from Aug 2003 to primary completion in Apr 2015, 139 months.
Results were first posted in Mar 2016, 10 months after primary completion.
Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 139 months is above that.
Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pirfenidone
Idiopathic Pulmonary Fibrosis →